A polymerase mechanism-based strategy for viral attenuation and vaccine development

Spencer A. Weeks, Cheri A. Lee, Yan Zhao, Eric D. Smidansky, Avery August, Jamie J. Arnold, Craig E. Cameron

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


Live, attenuated vaccines have prevented morbidity and mortality associated with myriad viral pathogens. Development of live, attenuated vaccines has traditionally relied on empirical methods, such as growth in nonhuman cells. These approaches require substantial time and expense to identify vaccine candidates and to determine their mechanisms of attenuation. With these constraints, at least a decade is required for approval of a live, attenuated vaccine for use in humans. We recently reported the discovery of an active site lysine residue that contributes to the catalytic efficiency of all nucleic acid polymerases (Castro, C., Smidansky, E. D., Arnold, J. J., Maksimchuk, K. R., Moustafa, I., Uchida, A., Götte, M., Konigsberg, W., and Cameron, C. E. (2009) Nat. Struct. Mol. Biol. 16, 212-218). Here we use a model RNA virus and its polymerase to show that mutation of this residue from lysine to arginine produces an attenuated virus that is genetically stable and elicits a protective immune response. Given the conservation of this residue in all viral polymerases, this study suggests that a universal, mechanism-based strategy may exist for viral attenuation and vaccine development.

Original languageEnglish (US)
Pages (from-to)31618-31622
Number of pages5
JournalJournal of Biological Chemistry
Issue number38
StatePublished - Sep 14 2012

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'A polymerase mechanism-based strategy for viral attenuation and vaccine development'. Together they form a unique fingerprint.

Cite this